ROBODREAD / SHUTTERSTOCK.COM
The CJEU’s decision in Forsgren has brought greater clarity to the scope of the SPC regulation, including whether a substance is an active ingredient, as Avi Toltzis and Penny Gilbert of Powell Gilbert explain.
On January 15, the Court of Justice of the European Union (CJEU) handed down its judgment in Forsgren (C-631/13). The judgment provides further guidance on the eligibility for supplementary protection certificates (SPCs) under articles 1(b) and 3(a), and 3(b) of regulation number 469/200—the SPC regulation.
The basic patent, EP0594610 (registered to Arne Forsgren), relates to protein D, which binds immunoglobulin D and is conserved in Haemophilus influenzae. Protein D is present in Synflorix, a pneumococcal vaccine for which GlaxoSmithKline Biologicals received a European marketing authorisation (MA) in 2009.
Synflorix is a vaccine composed of ten pneumococcal polysaccharide serotypes conjugated to a carrier protein, protein D, and absorbed by aluminium phosphate. The MA states that the vaccine is for use in active immunisation against diseases caused by Streptococcus pneumoniae.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
SPCs, CJEU, Forsgren, patent, Synflorix, GlaxoSmithKline